TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Candel Therapeutics ( (CADL) ) is now available.
On December 5, 2025, Candel Therapeutics will host a virtual R&D Day to provide an overview of its viral immunotherapy approach and oncology pipeline. This event is significant as it highlights the company’s progress in developing therapies like CAN-2409 and CAN-3110, which have shown positive clinical trial results and received regulatory designations. The event underscores Candel’s strategic positioning in the oncology market and its potential impact on stakeholders by advancing its pipeline and preparing for commercialization.
The most recent analyst rating on (CADL) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Candel Therapeutics stock, see the CADL Stock Forecast page.
Spark’s Take on CADL Stock
According to Spark, TipRanks’ AI Analyst, CADL is a Underperform.
Candel Therapeutics is currently facing substantial financial challenges with no revenue and ongoing cash burn, which heavily weighs down its stock score. Despite positive clinical trial results offering future potential, the current technical and valuation metrics remain unfavorable, reflecting the speculative nature of the stock.
To see Spark’s full report on CADL stock, click here.
More about Candel Therapeutics
Candel Therapeutics is a company in the biotechnology industry, focusing on viral immunotherapy and oncology. Their primary products include CAN-2409, a pan-solid tumor therapy, and CAN-3110, an oncolytic HSV-1 for tumor-specific replication. The company is advancing multiple programs in large indications and has received various designations such as RMAT and Orphan Drug for its products.
Average Trading Volume: 776,011
Technical Sentiment Signal: Sell
Current Market Cap: $288.8M
Learn more about CADL stock on TipRanks’ Stock Analysis page.